Monoclonal Antibody Outpatient Study Launches For COVID-19 Patients

Sorrento Therapeutics announced the U.S. FDA acceptance of its Investigational New Drug application for its Phase 1 clinical trials for intravenous (IV) STI-2020 (COVI-AMG). The trials will evaluate the safety, pharmacokinetics, and efficacy of a single injection of STI-2020 in healthy volunteers and outpatient COVID-19 patients with mild symptoms.

“Since COVI-AMG comes in a small volume IV-push formulation, made possible by the high potency of this unique antibody, we expect trials to enroll very quickly. This combination potentially makes STI-2020 an ideal candidate for the early treatment of SARS-CoV-2 infection in an outpatient setting,” stated Mike Royal, MD, Chief Medical Officer of Sorrento.